Leserbrief
Genotype-Guided vs Conventional Oral P2Y12 Inhibitors in Acute Coronary Syndrome
JACC: Cardiovascular Interventions · 2026-05 · 19 (9) · 1192
DOI: 10.1016/j.jcin.2026.02.044 ↗Kurz gefasst
Leserbrief in der Zeitschrift JACC: Cardiovascular Interventions, 2026-05. Verfasst von Amir Lotfi. Beteiligte Einrichtung: Division of Cardiology, Baystate Medical Center, Springfield, Massachusetts. Electronic address: amir.lotfi@baystatehealth.org. Die Arbeit nennt 3 Literaturangaben.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Autor:innen und Institutionen
- Division of Cardiology, Baystate Medical Center, Springfield, Massachusetts. Electronic address: amir.lotfi@baystatehealth.org.
Zitieren
APA
Lotfi, A. (2026). Genotype-Guided vs Conventional Oral P2Y12 Inhibitors in Acute Coronary Syndrome. JACC: Cardiovascular Interventions, 19(9), 1192. https://doi.org/10.1016/j.jcin.2026.02.044
Vancouver
Lotfi A. Genotype-Guided vs Conventional Oral P2Y12 Inhibitors in Acute Coronary Syndrome. JACC: Cardiovascular Interventions. 2026;19(9):1192. doi:10.1016/j.jcin.2026.02.044
BibTeX
@article{Lotfi2026,
author = {Lotfi, Amir},
title = {Genotype-Guided vs Conventional Oral P2Y12 Inhibitors in Acute Coronary Syndrome},
journal = {JACC: Cardiovascular Interventions},
year = {2026},
volume = {19},
number = {9},
pages = {1192},
doi = {10.1016/j.jcin.2026.02.044}
}
EUVIMED